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Background: Elevated plasma levels of the branched-chain amino acid (BCAA) leucine are associated with obesity
and insulin resistance (IR), and thus the propensity for type 2 diabetes mellitus development. However, other clinical
studies suggest the contradictory view that leucine may in fact offer a degree of protection against metabolic syndrome.
Aiming to resolve this apparent paradox, we assessed the effect of leucine supplementation on the metabolism
of human hepatic HepG2 cells.
Results: We demonstrate that pathophysiological leucine appears to be antagonistic to insulin, promotes glucose
uptake (and not glycogen synthesis), but results in hepatic cell triglyceride (TG) accumulation. Further, we provide
evidence that myostatin (MSTN) regulation of AMP-activated protein kinase (AMPK) is a key pathway in the metabolic
effects elicited by excess leucine. Finally, we report associated changes in miRNA expression (some species previously
linked to metabolic disease etiology), suggesting that epigenetic processes may contribute to these effects.
Conclusions: Collectively, our observations suggest leucine may be both ‘friend’ and ‘foe’ in the context of metabolic
syndrome, promoting glucose sequestration and driving lipid accumulation in liver cells. These observations provide
insight into the clinical consequences of excess plasma leucine, particularly for hyperglycemia, IR and nonalcoholic fatty
liver disease (NAFLD).
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The relative nutrient abundance that is associated with
modern Western dietary patterns causes a rapid increase
in postprandial plasma glucose and insulin levels and is
associated with a propensity toward the development of
metabolic syndrome characterized by visceral obesity, in-
sulin resistance (IR) and type 2 diabetes mellitus (T2DM).
The branched-chain amino acids (BCAAs) account for
15% to 25% of the total protein intake in the modern diet
[1], and increased plasma levels are clinically associated
with an obese phenotype [2] and progression to T2DM
[3,4]. Indeed, the levels of BCAAs are more strongly asso-
ciated with IR than are many of the common circulating* Correspondence: a.sheppard@auckland.ac.nz
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article, unless otherwise stated.lipid species [2] and may even be predictive indicators of
future T2DM risk [4]. However, whether elevated BCAAs
directly promote progression of metabolic syndrome
remains unclear, some studies even suggesting that the
BCAA leucine offers a level of protection against IR, ei-
ther by increasing muscle glucose utilization [5] or by
energy expenditure in thermogenic tissues [6].
To address this somewhat contradictory clinical picture,
we explored the phenotypic and molecular changes in-
duced in hepatic cells following leucine supplementation.
As previously reported for an in vivo study [7], we also
report enhanced glucose uptake in vitro, a presumed
benefit for limiting the onset of IR. However, we also
find increased de novo hepatic lipogenesis and triglyceride
(TG) deposition. Human and animal studies link high
glycemic diets with increases in hepatic fat storage, steatosistral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Western lifestyle of nutrient abundance and physical activ-
ity [9]. Thus, leucine is perhaps both ‘friend and foe’ in the
context of metabolic syndrome. We also report central
roles for myostatin (MSTN)-dependent AMP-activated
protein kinase (AMPK) signaling and miRNA-dependent
epigenetic processes in these metabolic effects.
Results
Leucine changes hepatic glucose and triglyceride
homeostasis
To examine the effect of increased leucine on hepatic
glucose utilization, we first assessed uptake by HepG2
cells. Compared to untreated controls, basal 2-deoxy-
D-[1,2-3H] glucose (2-DOG) uptake was significantly in-
creased (25% and 33%) with 0.1 mM and 2.5 mM leucine,
respectively (P ≤0.05; Figure 1A). Interestingly, insulin-
stimulated 2-DOG uptake was further enhanced (50% and
71%) in the presence of leucine (P ≤0.05), indicating that
leucine may augment glucose utilization independent of
insulin. As we found no evidence that leucine stimulated
glucose secretion (Figure 1B), we suggest that its primary












































Figure 1 Effect of leucine supplementation on glucose and lipid me
consumption with or without the addition of insulin (1nM). Total intracellular gl
secreted into the media with or without addition of insulin (1nM). (C) Tot
content. (D) Glycogen content of homogenized samples treated with glucoamy
to total protein content. Values are presented as mean ± SEM. Statistical significaWe questioned whether this increase in glucose uptake
resulted in enhanced conversion to lipids by measuring
total intracellular TG, which increased significantly (16%
and 21%) at 0.1 mM and 2.5 mM of leucine respectively
compared to the untreated control (P ≤0.05; Figure 1C).
Moreover, cellular glycogen was unchanged after leucine
supplementation (Figure 1D).
Leucine changes hepatic expression of glucose/lipid sensing
genes
Excessive hepatic glucose uptake is likely to contribute to
the development of obesity-related dyslipidemia. To provide
molecular evidence for the role of leucine in perturbing
hepatic metabolism, mRNA expression levels of several
key genes involved in lipid and glucose sensing were
measured. The expression of pyruvate carboxylase (PC),
a ligase that catalyzes the carboxylation of pyruvate to
oxaloacetate [10]; phosphoenolpyruvate carboxykinase
(PCK1; PEPCK), which decarboxylates and phosphory-
lates oxaloacetate into phosphoenol pyruvate [10]; and
glucose 6-phosphatase (G6Pase), which catalyzes the final
steps of gluconeogenesis, resulting in production of glucose
[11], were measured. Although PC and PCK1 expression
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tabolism in HepG2 cells. (A) 2-deoxy-D-[1,2-3H] glucose (2-DOG)
ucose uptake was normalized to total protein content. (B) Levels of glucose
al intracellular amount of triglyceride (TG), normalized to total protein
lase to hydrolyze glycogen into glucose. Glycogen amount was normalized
nce relative to untreated control, *P <0.05, **P <0.01 (n =3).
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addition, the mRNA level of solute carrier family member2
(SLC2A2) was increased (P ≤0.05) by 34% at 0.1 mM and
46% at 2.5 mM of leucine. Moreover, peroxisome prolifera-
tive activated receptor-γ co-activator 1 (PPARγ) expression,
a stimulator of endogenous SLC2A2 mRNA transcription
and key regulator of the genes associated with steatosis liver
[12], was enhanced by about 40% after the leucine treat-



































































































































































Figure 2 Expression of the genes involved in glucose and lipid sensin
(qPCR) and immunoblotting analysis of expression levels of genes involve
immunoblotting analysis of specific upstream genes involved in glucose/lipid
with leucine for 48 h. Values are presented as mean ± SEM. Statistical significaforkhead box protein A2 (FOXA2), which synergistically
increases the promoter activity of the SLC2A2 gene [13],
was also increased by 33% (P ≤0.05; Figure 2A). We also
found a significant increase in glucokinase (GK), 33.3% at
2.5 mM (P ≤0.05; Figure 2A).
Glycerol-3-phosphate acyltransferase (GPAT1) catalyzes
glycerol synthesis and thus TG biosynthesis [14]. GPAT1 ex-
pression was increased by 33% at 2.5 mM leucine (P ≤0.05;

































































g after leucine supplementation of HepG2 cells. (A) Real-time PCR
d in gluconeogenesis, glucose uptake and lipogenesis. (B) qPCR and
sensing. Western blotting was performed using cell lysates supplemented
nce relative to untreated control, *P <0.05 (n =3).
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at 2.5 mM leucine (P ≤0.05; Figure 2A). Collectively, our
data indicate that leucine supplementation promotes hepatic
lipid synthesis; however, they do not demonstrate that over-
expression of SLC2A2 and GPAT1 alone mediate the effect
of leucine on glucose uptake and triglyceride biosynthesis.
PPARGC1A and forkhead transcription factor (FOXO1)
play important roles in glucose metabolism [16], and nu-
clear accumulation of the latter also stimulates TG synthe-
sis [17]. Expression of both increased by 54% (P ≤0.05)
and 37%, respectively (Figure 2B). Activated protein kinase
B (AKT) phosphorylates FOXO1 [18] to prevent nuclear
translocation, yet we found that (Ser473)-AKT phosphoryl-
ation was reduced by about 30% at both 0.1 mM and
2.5 mM leucine, suggesting that FOXO1 was not only up-
regulated but functionally activated by leucine.
mTORC1 (mammalian target of rapamycine complex 1),
a nutrient and hormonal sensor [19], regulates gene trans-
lation through phosphorylation and activation of ribosomal
protein S6 kinase beta-1 (S6K1) [20]. We found either
mTORC1 activity or S6K1 phosphorylation remained un-
changed (Figure 3A). In addition to mTOR, AKT activity



























































Figure 3 AMP-activated protein kinase (AMPK) but not mammalian targ
(mTOR/ S6K1) activity was regulated by leucine in HepG2 cells. (A) West
stained for p-mTOR and p-S6K1 and (B) p-AMPK. (C) Effect of leucine supplem
mean ± SEM. Statistical significance relative to untreated control, *P <0.05, (n =also negatively regulates p(Thr172)- AMPK-α [21]. Leucine
enhanced phosphorylation of (Thr172)- AMPK-α by 40%
(P ≤0.05) and 50% (P ≤0.01) at 0.1 mM and 2.5 mM, re-
spectively (Figure 3B).
Clinical obesity is associated with increased MSTN ex-
pression [22], and MSTN mRNA levels are increased in
both adipose and skeletal muscle of obese mice [23]. We
detected a fourfold increase in MSTN expression at 2.5 mM
leucine (P ≤0.05) (Figure 3C).
Myostatin is involved in the regulation of leucine modified
genes
To determine the effect of MSTN on the cellular glucose
uptake, we measured 2-DOG uptake in MSTN inhibited
cells followed by leucine supplementation (Figure 4A).
In the basal state, siRNA-mediated knockdown of MSTN
led to a 40% (P ≤0.05) decrease in glucose uptake whereas
in the presence of leucine, MSTN suppression led to 40 to
60% (P ≤0.05) reduction in glucose uptake across the vari-
ous leucine doses, suggesting an MSTN-dependent effect
of leucine on promoting glucose uptake. Next, we hypoth-
esized that MSTN promoted leucine-mediated glucose up-
take via AMPK activation and indeed found that MSTN (mM)
 2.5
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ern blots and densitometry analysis of leucine-supplemented HepG2 cells





























































































































































































































MSTN              +                     -
*
Figure 4 Effects of myostatin (MSTN) on AMP-activated protein kinase (AMPK) activity and glucose /lipid sensing in leucine- treated HepG2
cells. (A) Glucose uptake is repressed in MSTN-suppressed cells. MSTN knock-down efficiency using siRNA (B) The leucine- induced AMPK signaling
pathway was suppressed following MSTN suppression. (C) mRNA levels of leucine-sensitive genes in the presence and absence of MSTN. Values are
presented as the mean ± SEM. Statistical significance relative to untreated control, *P <0.05, **P <0.01 (n =3).
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in the presence of both 0.1 mM and 2.5 mM leucine
(P ≤0.05), while p(Thr172)-AMPK levels remained unchanged
(with and without MSTN-knockdown) in the absence of leu-
cine (Figure 4B). These results suggest that leucine-induced
AMPK phosphorylation is mediated byMSTN signaling.
To identify which of the leucine-responsive genes were
regulated by MSTN, we measured candidate mRNA
expression following MSTN inhibition. As shown in
Figure 4C, expression of most of them was markedly
reduced (37% to 75%; P ≤0.01). ACC1 and PPARγ were
notable exceptions.
miRNA array validation using quantitative real-time PCR
Hierarchical clustering using Pearson correlation identi-
fied 35 and 5 human miRNAs to be significantly up- or
downregulated, respectively by 2.5 mM leucine compared
to untreated controls (Figure 5A). We validated the ex-
pression of leucine-dependent microRNAs in HepG2 cells,
including miR-143, miR-92b*, miR-335, miR-181d, miR-
3185 and miR-4763 by real-time PCR (qPCR) (Table 1).
As expected, the expression of miRNA-143 was reduced
1.5-fold (P ≤0.05), while that of miRNA-92b* and miR-335
was upregulated 1.8- and 1.5-fold (P ≤0.05) at 2.5 mM of
leucine, respectively (Figure 5B). However, there was no
significant difference in the expression of miR-181d, miR-
3185 and miR-4763.
To confirm whether up/downregulated miRNAs can
modulate leucine’s effects on glucose and lipid metabol-
ism, we measured the expression of leucine-dependent
genes of interest in suppressed (or not) miRNAs. Following
miR-143 suppression, leucine supplementation induced a
significant increase in PPARγ expression by 6- and 8.6-fold
at 0.1 mM and 2.5 mM leucine, respectively, compared to
cells without miR-143 suppression (Figure 5C). This is in
contrast to our earlier observation that leucine induced a
modest 1.6-fold increase in HepG2 cells (without miR-143
suppression; Figure 2A), suggesting an inhibitory effect of
miR-143 on PPARγ via leucine.
Also, we found increased MSTN level (1.8-fold; P ≤0.05)
in the absence of leucine (Figure 5C). On the contrary,
miRNA-143 suppression led to a reduced MSTN expres-
sion by 50% (P ≤0.01) in the presence of leucine, suggesting
that MSTN is also regulated in a miR-143 dependent man-
ner. Notably, leucine supplementation did not promote
FOXA2 expression (Figure 5C). Suppression of miR-92b*
tended to reduce gene expression of MSTN in the absence
of leucine but increased the MSTN level with the 2.5 mM
leucine treatment, despite being statistically not significant
(Figure 5D). Although not statistically significant, there
was also a decrease in both SLC2A2 and FOXA2 expres-
sion, but only in the presence of leucine (Figure 5D). Also,
FOXO1 expression was increased by 1.5-fold (P ≤0.05) in
the absence of leucine (Figure 5D). Finally, following miR-335 suppression, SLC2A2 expression was reduced by 50%
(P ≤0.01) in the presence and absence of leucine, but
FOXO1 expression was unchanged (Figure 5E). Collect-
ively, these data indicate miRNAs influence key metabolic
genes, either directly or in response to leucine.
Discussion
The intake of dietary protein (BCAAs) influences glucose
metabolism and insulin sensitivity. Both IR and T2DM
associated with metabolic syndrome often correlate with
considerable changes in amino acid metabolism [24]. We
show that elevated leucine increases glucose uptake by
HepG2 cells and activates the glucokinase gene, the apical
sensor of intracellular glucose levels (Figure 6). Further,
we suggest this enhanced glucose uptake may be a conse-
quence of increased SLC2A2 gene transcription, resulting
from increased expression of FOXA2 a critical down-
stream effector of metabolic processes and transcription
factor known to promote SLC2A2 transcription [13]. Mean-
while, we do not see evidence for glucose secretion or for
any change in the PEPCK and PC gene transcription,
implying that leucine does not promote gluconeogenesis.
However, we did note increased G6Pase transcription.
Although often linked to gluconeogenesis, the key cellular
role of G6Pase in buffering G6P concentrations is also
dependent on the processes of glycolysis and glycogenolysis
[11]. Further, we did not observe any increase in glycogen
content, rather a tendency towards decreasing glycogen.
The primary regulation of systemic glucose levels by
insulin is triggered when hepatic receptors recruit the
insulin receptor substrate (IRS), leading to activation
(phosphorylation) of PI3K/AKT and in turn phosphoryl-
ation of FOXO1, which blocks its nuclear translocation and
inhibits activation of gluconeogenic genes (notably PEPCK
and PC) to reduce net cellular glucose output [18]. How-
ever, under our culture conditions of basal insulin and sup-
plemented leucine, phosphorylation of AKT was markedly
decreased, suggesting that leucine is antagonistic to insulin,
at least with respect to the regulation of AKT activity.
When activated, AKT also suppresses the phosphorylation
and activity of the serine/threonine kinase AMPK [21], an
intracellular energy regulator influencing both glucose and
lipid metabolism. Thus, with leucine supplementation the
suppression of AKT would have been predicted to promote
an AMPK-dependent increase in the terminal pathway ef-
fector mTORC1 [19]. However, we observed both a de-
crease in mTORC1 phosphorylation (leading to activation)
and unchanged levels of mTORC1-dependent S6K1 phos-
phorylation. Collectively, then, our data suggest this seminal
pathway is central to leucine-dependent glucose sensing.
Recently, AMPK regulation of the TGFβ family mem-
ber MSTN has been linked to acute increases in glucose
transport and IR [25,26]. MSTN mRNA levels are elevated
in peripheral tissues from obese, leptin-deficient ob/ob
Figure 5 (See legend on next page.)
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Figure 5 Discovery and validation of miRNA expression after leucine supplementation. (A) Cluster analysis of miRNAs available on Affymetrix
miRNA chips. The red color shows relatively abundant expression of the same miRNA when compared to controls, whereas the blue color indicates a
low expression relative to other samples. Cluster analysis was performed with Gene Spring GX. (B) Validation of specific miRNA species exhibiting
significant difference from the control group, using real-time PCR (qPCR). Finally, differential expression of specific target genes measured after
inhibition of miR-143 (C), miR-92b*(D) and miR-335 (E) using selective siRNAs. Values are presented as the mean ± SEM. Statistical significance
relative to untreated control, *P <0.05, **P <0.01 (n =3).
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glucose uptake in vitro by C2C12 myotubes [27]. Mean-
while, MSTN knock out enhances systemic insulin sen-
sitivity and prevents obesity [28,29]. Clinically, plasma
levels of MSTN protein are elevated in obese patients
[22,30] and a comparison of muscle cells isolated from
obese and non-obese women revealed increased MSTN
secretion [22]. Conversely, MSTN mRNA levels are re-
duced in peripheral tissues following weight loss in mice
and human patients [31,32]. Our observations are parsi-
monious with these collective observations, providing
perhaps the first empirical data supporting increased
hepatic glucose uptake in the presence of excess extra-
cellular leucine and suggesting that it occurs through
MSTN-dependent AMPK modulation of glucose trans-
porter expression.
While AMPK activates glucose transport and glycolysis
in skeletal muscles, it also suppresses glycogenolysis [33],
and we reported a mild reduction of glycogen in hepatic
cells, but also an accumulation of fats. Under normal con-
ditions, the excess glucose is converted into lipids carried
as very-low-density lipoprotein (VLDL) and ultimately
stored as TG. However, under chronic conditions of
glucose uptake, pathologic levels of TG accumulation
can occur and a fatty liver phenotype may develop. As
described above we show leucine-dependent accumulation
of FOXO1, which promotes transcription of microsomal
TG transfer protein (MTP) and VLDL production and
leading to hepatic hypertriglyceridemia [17]. With leucine
supplementation we see elevated transcription of several
genes involved in fatty acid synthesis, including GPAT1,
ACC1 and PPARγ. GPAT1 is a key enzyme in the regula-
tion of hepatic triglyceride biosynthesis, such that an acute
reduction of mitochondrial GPAT1 in the liver of ob/obTable 1 Real-time PCR (qPCR) validation of differentially
expressed microRNAs in leucine-treated HepG2 cells
compared with control






hsa-miR-4763 1.22mice reduces triglyceride synthesis and obesity [14].
Expressed at high levels in lipogenic tissues, ACC1 controls
the regulation of long-chain fatty acids biosynthesis, and its
inhibition has been proposed as a potential strategy for the
treatment of obesity and related disorders [15]. In addition,
PPARγ binds to the promoters of SLC2A2 and GK [12]
activating transcription, and when overexpressed leads
to lipid accumulation in hepatocytes [34]. We observe
analogous in vitro transcriptional changes, consistent with
the stimulation of hepatic lipogenesis after leucine supple-
mentation and again, these effects appear to require
MSTN-dependent AMPK signalling. GPAT1 expression in
particular, was significantly altered by MSTN suppression
in our experiments.
In MSTN-null mice, the insulin sensitivity of skeletal
muscle is improved and body fat reduced [35,36]. Further,
a constitutive MSTN loss-of-function mutation also at-
tenuates fat accumulation in muscle tissue and hepatic
steatosis in mice fed a high-fat diet [37]. The most common
cause of abnormal liver function is NAFLD [38], in which
increased TG synthesis contributes to hepatic steatosis and
is frequently a sequela observed with advancement of meta-
bolic syndrome. NAFLD may even cause pancreatic β-cells
to attempt compensation by increasing insulin production,
leading to hyperinsulinemia and in turn, further stimulating
hepatic de novo lipogenesis (reviewed by [39]). Emerging
data from both human and animal studies support a causal
role of intracellular hepatic TG accumulation in the patho-
genesis of hepatic IR and human NAFLD subjects often
exhibit peripheral IR as well [40].
We have also investigated a role for miRNA-mediated
epigenetic effects in the manifestation of the hepatic re-
sponses to leucine exposure. MicroRNAs have now been
linked to a variety of biological phenomena, and specific-
ally to insulin secretion [41,42], reduced viability and num-
bers of pancreatic β-cells [43], glucose metabolism [44]
and pathological development of obesity [45]. In particular,
expression of miR-143, miR-17-92b and miR-335 are sig-
nificantly altered in diet-induced obese mice [46], during
3 T3-L1 adipocyte differentiation [47], and in human adi-
pose tissues inflammation [48]. We found that suppression
of miR-143 led to a strong increase in the hepatic expres-
sion of PPARγ and blocked the ability of leucine to induce
both MSTN and FOXA2 expression. Meanwhile, it has
been reported that the miR-17-92 cluster, which yields six
mature miRNAs including miR-92, is upregulated and
Figure 6 Schematic summary of findings. Leucine supplementation promotes hepatic cell glucose uptake by upregulating solute carrier family
member2 (SLC2A2) expression via myostatin (MSTN). MSTN activity leads to the activation of AMP- activated protein kinase (AMPK) and inhibition
of glycogen synthesis. Furthermore, activation of MSTN leads to overexpression of genes involved in glucose uptake, which is further responsible
for triglyceride synthesis. Moreover, leucine supplementation alters the expression of several small RNA species including miR-143, miR-335 and
miR-92b*, which target main gene regulators of these effects.
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regulator and tumor suppressor gene Rb2/p130 [47]. We
found suppression of miR-92b* reduced the leucine-
dependent upregulation of MSTN, FOXO1, SLC2A2 and
FOXA2. Further, miR-335 upregulation combines with
increased expression of interleukin-6 and tumor necro-
sis factor-α during inflammation of human visceral adi-
pose tissue in obesity-related IR [48], and occurs in
parallel with that of PPARγ after the induction of 3 T3-
L1 adipocyte differentiation [41]. Notably, we found that
miR-335 suppression inhibited leucine-dependent in-
creases in FOXO1 and SLC2A2 gene expression.
Conclusions
In summary, we suggest that leucine may be both ‘friend’,
stimulating hepatic cell uptake of extracellular glucose,
and ‘foe’, with progression toward NAFLD-like pheno-
types being perhaps the unavoidable and obligatory
consequence of the enhanced glucose sequestration pro-
moted by extracellular leucine when in pathophysiological
excess. We also extend the potential functional import-
ance of the metabolic axis of AMPK-MSTN signaling and
miRNA mediated epigenetic mechanisms in the context of
metabolic syndrome and NAFLD in particular. We alsowill look to extend these encouraging findings to primary
cultures of hepatocytes in future studies. While out find-
ings may offer an intriguing resolution to the apparent
paradox associated with the reported pathophysiological
consequences of BCAA exposures, further investigation in
cultures of primary hepatocytes from clinical patients is
warranted to substantiate them.
Methods
Chemicals and antibodies
DMEM and FBS were from Invitrogen (CA, USA). The
2-DOG was from PerkinElmer (Boston, USA). All other
chemicals were from Sigma (St. Louis, MO, USA) un-
less otherwise stated. Antibodies for mTORC1, p(Ser2448)-
mTORC1, p(Thr389)-p70-S6K1, AMPKα, p(Thr172)-AMPKα,
AKT and p(Ser473)-AKT were from Cell Signaling
Technology (Boston, MA, USA) and B-actin antibody was
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The predesigned miRNA primers and siRNAs were from
Qiagen (Hilden, Germany).
Cell culture and treatment
The HepG2 cell line was purchased from American Type
Culture Collection (Manassas, VA, USA) and were
Table 2 Primer sequences used in real-time PCR (qPCR)
Gene name Primers Primer sequences
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FBS at 37°C with 5% CO2. Cells were seeded at 10
4 to 105
cells/cm2 and after 24 h treated (or not) with 0.1 mM or
2.5 mM leucine for 48 h before being harvested for vari-
ous assays. The survival of the cells was measured by an
MTTassay after 48 h of exposure to leucine.
Glucose uptake assay
HepG2 cells treated (or not) with leucine were washed
with pre-warmed PBS twice and incubated in a glucose-free
Krebs-Ringer phosphate buffer (KRP) buffer containing 1%
BSA for 1.5 h at 37°C. Glucose uptake assay was then per-
formed as described previously [49]. Results were normal-
ized against the total intracellular protein content, which
was determined by BCA assay (Thermoscientific, IL, USA).
Glucose output assay
Glucose secreted into the medium was measured using
Amplex Red Glucose Kit (Invitrogen, Carlsbad, NM, USA)
according to manufacturer’s instructions. Following leucine
treatment (or not), cells were washed twice with pre-
warmed PBS and incubated for 1.5 h in glucose produc-
tion assay medium (glucose and phenol red-free DMEM
containing 2 mM sodium pyruvate and 20 mM sodium
lactate). Next, 1 nM insulin was added 10 min before the
end of the incubation period as appropriate. Media was
collected for analysis. Data were normalized against total
intracellular protein.
Triglyceride measurement
Total intracellular TG content was measured using a
fluorometric method kit (BioVision, CA, USA) in accord-
ance with the manufacturer’s instructions. Data were nor-
malized against total intracellular protein.
Glycogen measurement
The assay was performed using a Glycogen Assay Kit
(BioVision, CA, USA) according to the manufacturer’s
instructions. Glycogen content was normalized against the
total intracellular protein.
Real-time PCR
Total RNA was isolated from leucine-treated (or not)
HepG2 cells using PureLink RNA Mini Kit (Invitrogen,
CA, USA) and cDNA was synthesized from 2 μg of total
RNA using Transcriptor First Strand Synthesis kit (Roche,
Mannheim, Germany). qPCR analysis was carried out on a
LightCycler-480 II (Roche, Switzerland) in 10 μl volumes
containing Light Cycler 480 SYBR Green, 0.5 mM of
reverse or forward PCR primers (Table 2) and 1 μl of
first-strand cDNA. The endogenous control peptidyl-prolyl
isomerase A (PPIA) gene expression was chosen as the
housekeeping gene as its threshold was constant across
different conditions. The mRNA expression levels werenormalized against PPIA by subtracting its average cycle
threshold from the average threshold for each cDNA sam-
ple yielding a level of mRNA expression for the target
molecule relative to the endogenous RNA reference gene.
Western blotting
HepG2 cells (treated or not) were washed twice with ice-
cold PBS. Ice-cold TK lysis buffer was added containing
protease and phosphatase inhibitors. A total of 20 μg
protein from whole cell lysates was resolved using 10%
SDS-PAGE followed by transfer onto Immobilon-P PVDF
membrane (Millipore, MA, USA). Primary and second-
ary antibodies were diluted in 2% skim-milk/PBS-0.1%
Tween 20.
Reverse transfection
MSTN siRNA (4392420-s5679, Invitrogen, CA, USA) or
control oligonucleotides (4390843, Invitrogen, CA, USA)
were reverse transfected into HepG2 cells in a 24-well plate
using Lipofectamine RNAiMAX (Invitrogen, CA, USA).
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Opti-MEM I Medium (Invitrogen, NY, USA) and incubated
in wells for 20 min. Cells were then added at a density of
105 cells/well and 24 h later treated with leucine for a
further 48 h before being harvested.miRNA microarray
A PureLink RNA Mini Kit was used to extract total RNA
(Invitrogen, CA, USA). The RNA was initially evaluated by
260/280 ratio using a NanoDrop ND-1000 Spectropho-
tometer (NanoDrop Technologies, DE, USA) and was
further assessed on Agilent 2100 Bioanalyzer (Agilent
Technologies, CA, USA) after preparation with an Agilent
RNA 6000 Nano kit. All samples showed values of 260/
280 above 1.8 and RIN scores of at least 8.0. Reverse
transcription was carried out using 500 ng total RNA.
Then, cRNA was labeled with Biotin using Affymetrix Flash
Tag Biotin HSR RNA Labeling kit. The fragmented-Biotin-
labeled cRNA was then added to the array (Affymetrix
GeneChip miRNA 3.0), and after washing to remove any
unbound RNA , hybridization was assessed by fluorescent
staining (GeneChip Hybridization, Wash and Stain kit)
and scanning with a GeneChip Scanner 3000 system.
Robust multi-array average (RMA) background correc-
tion and quartile normalization were used to adjust signal
intensity data. All data then were converted into log2
values for further statistical analysis.Validation of miRNA expression/ gene targets
Candidate targets for validation by qPCR were deter-
mined according to both fold-change and significance at
P ≤0.05. Also, miRBase (http://microrna.sanger.ac.uk/)
and miRWalk (http://www.umm.uni-heidelberg.de/apps/
zmf/mirwalk/index.html) databases were used to identify
potential and validated gene targets. The cDNA synthesis
was carried out with 2 μg total RNA using a miScript II
RT Kit (Qiagen, Hilden, Germany) , and expression of the
miR-143, miR-92b*, miR-335, miR-181d, miR-3185 and
miR-4763 was assayed with a a miScript SYBR Green PCR
kit (Qiagen, Hilden, Germany). Data was normalized to
RNU6-2 snRNA expression. Commercially available siR-
NAs were used to inhibit differentially expressed miRNAs
(Qiagen, Hilden, Germany) following qPCR to assess
target gene effects.Statistical analysis
All analyses were performed using the IBM SPSS statis-
tical program (version 21, NY, USA). All results are pre-
sented as mean ± SEM from at least three independent
experiments done in triplicates. A one-way ANOVA with a
Tukey post-hoc test was used to assess differences between
groups. P ≤0.05 was considered statistically significant.Abbreviations
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